Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events

NCT01859754 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT01859754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01859754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events
Lead sponsor
Octapharma
Phase
Observational
Overall status
Completed
Start date
May 21, 2013
Completion date
May 22, 2019
Enrollment
623 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune deficiency disorder